Process Development Toward Serum-Free Mesenchymal Stem Cells

by Alexey Bersenev on June 17, 2014 · 0 comments

in cell culture, mesenchymal

Post to Twitter Send Gmail Post to LinkedIn

this is sponsored post

“Regulatory approval relies on the ability to consistently manufacture human MSCs”

Quality, consistency and scalability are the key reasons that mesenchymal stem cell (MSC) research has shifted from serum-containing to serum-free media, as stated by Loughborough University’s Dr. Qasim Rafiq at this year’s International Society for Cell Therapy (ISCT) conference. His talk, joined by Irvine Scientific’s Dr. Jessie Ni, discussed the development of an optimal serum-free MSC expansion medium and the approach to scaling up MSC production. Together, their presentations explored how serum-free and validated MSC media development can translate into a cost-effective and consistent cell culture platform for basic research and clinical applications.

The two presentations have been made available by Irvine Scientific for viewing.
Custom Serum-Free Media Development & Optimization: A Molecular Approach to Productivity & Quality
Jessie H.-T. Ni, PhD. Chief Scientific Officer, Irvine Scientific

  • Serum-free is independent of the serum supply chain, friendly towards regulatory affairs, and less lot-to-lot variation
  • PRIME-XV™ MSC Expansion SFM design input includes basal media optimization, serum albumin qualification, and growth factor optimization
  • MSC validation focuses on phenotype, cell surface marker expressions, multipotency and immune modulation
  • Similar approach can be applied for other serum-free media development, such as xeno-free, serum-free T-cell expansion medium
  • “Quality-driven” approach results in effective final product performance

Process Development Strategies Toward Serum-Free Liter-Scale Expansion of Human Mesenchymal Stem Cells
Qasim Rafiq, PhD. E-TERM Research Fellow, Loughborough University

  • Spent media analysis was done to examine nutrient consumption of human MSCs cultured in serum versus serum-free media.
  • PRIME-XV™ MSC Expansion SFM were compared versus serum-containing medium for fold expansion, population doublings, glucose consumption, lactate/ammonium production,, cellular metabolite flux, morphology, marker expression
  • Different commercially available serum-free media were compared by cost, user-friendliness, and viable cell number. PRIME-XV™ MSC Expansion SFM showed a far higher total viable cell count versus many competitors
  • Economies of scale far more favored with PRIME-XV™ MSC Expansion SFM for product performance and cost

If you are interested in sampling Irvine Scientific’s PRIME-XV™ MSC Expansion SFM or its upcoming PRIME-XV™ T-cell Expansion XSFM, please contact them here.

{ 0 comments… add one now }

Leave a Comment

Previous post:

Next post: